Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment
Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment
Active, not recruiting · NCT07565948 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment | Blood-Borne Infections, Digestive System Diseases, Flaviviridae infectious disease, Infections, RNA Virus Infections, hepatitis, hepatitis C virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Not stated | 2026-05-04 | NCT07565948 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xiangya Hospital of Central South University | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Xiangya Hospital of Central South University | Changsha | China | 16 |